QCG
CERE

Quadrant Capital Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Quadrant Capital Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-120
Closed -$4.91K – 2812
2024
Q2 		$4.91K Hold
120
– – ﹤0.01% 2295
2024
Q1 		$5.07K Hold
120
– – ﹤0.01% 2311
2023
Q4 		$5.09K Buy
120
+14
+13% +$402 ﹤0.01% 2274
2023
Q3 		$2.31K Buy
+106
New +$2.65K ﹤0.01% 2354
2023
Q1 		– Sell
-45
Closed -$1.42K – 2809
2022
Q4 		$1.42K Buy
+45
New +$1.27K ﹤0.01% 2481

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Quadrant Capital Group's CERE Position: Q3 2024 in Review

Quadrant Capital Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 120 shares — an estimated $4.91K sold.

Quadrant Capital Group first reported a position in CERE in Q4 2022 and held it in 5 quarters. The position peaked at $5.09K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Quadrant Capital Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 120 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $4.91K.
  • Quadrant Capital Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 5 quarters.
  • Quadrant Capital Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $5.09K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Quadrant Capital Group's 13F filing for Q3 2024, filed 12 Nov 2024.